Brief: Carisma Therapeutics Granted FDA Fast Track Designation For CT-0525 For The Treatment Of HER2-Overexpressing Solid Tumors
25/06/2024 12:34
June 25 (Reuters) - Carisma Therapeutics Inc CARM.O :
* CARISMA THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION
FOR
CT-0525 FOR THE TREATMENT OF HER2-OVEREXPRESSING SOLID TUMORS
* CARISMA THERAPEUTICS INC: INITIAL PHASE 1 DATA EXPECTED BY
YEAR-END 2024
Source text for Eikon: ID:nPn9Jdnfja
Further company coverage: CARM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary